ADAPTIN BIO, INC.

Clinical/early-stage biotech — near-insolvent.

Strengths

• Liquidity — current ratio 0.29 (7th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Weak liquidityCurrent ratio 0.29 (<1)
• Buying back stockNet buyback — share count -19%/yr over 2y